|
US5672659A
(en)
|
1993-01-06 |
1997-09-30 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
|
CA2158745C
(en)
|
1993-03-25 |
2007-06-19 |
Richard L. Kendall |
Inhibitor of vascular endothelial cell growth factor
|
|
US5595760A
(en)
|
1994-09-02 |
1997-01-21 |
Delab |
Sustained release of peptides from pharmaceutical compositions
|
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Ｖｅｇｆ結合性ポリペプチド
|
|
US6100071A
(en)
*
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
JP3011144B2
(ja)
|
1997-07-31 |
2000-02-21 |
日本電気株式会社 |
光スキャナとその駆動方法
|
|
CN101433715B
(zh)
|
1999-06-08 |
2013-04-17 |
里珍纳龙药品有限公司 |
具有改善的药物动力学特性的修饰嵌合多肽
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US6833349B2
(en)
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7141607B1
(en)
|
2000-03-10 |
2006-11-28 |
Insite Vision Incorporated |
Methods and compositions for treating and inhibiting retinal neovascularization
|
|
EP1938799B1
(en)
|
2000-03-10 |
2013-05-08 |
Insite Vision Incorporated |
Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
|
|
WO2004110490A2
(en)
|
2003-06-06 |
2004-12-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US7582726B2
(en)
|
2003-11-10 |
2009-09-01 |
Ghc Research Development Corporation |
VEGF receptor antagonists
|
|
CA2567686A1
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
|
RU2007117716A
(ru)
*
|
2004-10-12 |
2008-11-20 |
Ампротеин Корпорейшн (Us) |
Химерный белок
|
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
EP1853298A2
(en)
|
2005-02-11 |
2007-11-14 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
KR20070114753A
(ko)
|
2005-02-18 |
2007-12-04 |
아브락시스 바이오사이언스 인크. |
치료제의 조합 및 투여 방식, 및 조합 요법
|
|
ES2633574T3
(es)
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
|
CA2615636A1
(en)
|
2005-08-12 |
2007-02-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of diseases by subcutaneous administration of a vegf antagonist
|
|
AU2006279541A1
(en)
|
2005-08-15 |
2007-02-22 |
The Regents Of The University Of California |
VEGF-activated FAS ligands
|
|
CN100471872C
(zh)
*
|
2005-11-04 |
2009-03-25 |
余波 |
包含vegf受体片段的优化融合蛋白质及其医疗应用
|
|
CA2630839C
(en)
|
2005-12-16 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with dll4 antagonists
|
|
US7354582B2
(en)
|
2006-03-10 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF antagonists for the treatment of malignant gliomas
|
|
NZ615012A
(en)
|
2006-03-21 |
2015-11-27 |
Genentech Inc |
Combinatorial therapy involving alpha5beta1 antagonists
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
CA2670707A1
(en)
|
2006-12-11 |
2008-06-19 |
Genentech, Inc. |
Compositions and methods for treating a neoplasm
|
|
CN101205252A
(zh)
|
2006-12-14 |
2008-06-25 |
上海中信国健药业有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
CL2008002782A1
(es)
|
2007-09-21 |
2009-07-31 |
Genentech Inc |
Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
|
|
CN101575379B
(zh)
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
CN102317320A
(zh)
*
|
2008-12-11 |
2012-01-11 |
韩国科学技术院 |
能够结合于VEGF-A和TNF-α的融合蛋白
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
KR101248912B1
(ko)
*
|
2009-12-31 |
2013-03-29 |
한양대학교 산학협력단 |
항혈관신생 활성을 가지는 재조합 아데노바이러스
|
|
EP3327032A1
(en)
|
2010-08-06 |
2018-05-30 |
Genzyme Corporation |
Vegf antagonist compositions and uses thereof
|
|
KR20190049934A
(ko)
|
2011-01-13 |
2019-05-09 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
CN102219859B
(zh)
|
2011-05-20 |
2012-09-12 |
烟台荣昌生物工程有限公司 |
拮抗血管新生诱导因子的融合蛋白及其用途
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
WO2013106765A1
(en)
|
2012-01-13 |
2013-07-18 |
Genentech, Inc. |
Biological markers for identifying patients for treatment with vegf antagonists
|
|
WO2013152351A2
(en)
*
|
2012-04-06 |
2013-10-10 |
The Trustees Of Columbia University In The City Of New York |
Fusion polypeptides and methods of use thereof
|
|
CN102924604A
(zh)
*
|
2012-11-01 |
2013-02-13 |
中国人民解放军军事医学科学院生物工程研究所 |
重组血管内皮生长因子受体及其编码基因与应用
|
|
MX373894B
(es)
|
2012-11-08 |
2020-07-09 |
Clearside Biomedical Inc |
Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
|
|
TW201427989A
(zh)
|
2012-12-18 |
2014-07-16 |
Novartis Ag |
長效性蛋白質之組合物及方法
|
|
CN105188733B
(zh)
*
|
2013-03-13 |
2020-05-08 |
建新公司 |
包含pdgf和vegf结合部分的融合蛋白及其使用方法
|
|
WO2015000181A1
(zh)
*
|
2013-07-05 |
2015-01-08 |
华博生物医药技术（上海）有限公司 |
新型重组融合蛋白及其制法和用途
|
|
CA2922483A1
(en)
|
2013-09-11 |
2015-03-19 |
Neurotech Usa, Inc. |
Encapsulated cell therapy cartridge
|
|
WO2015109898A1
(zh)
|
2014-01-24 |
2015-07-30 |
上海恒瑞医药有限公司 |
VEGF与PDGFRβ双特异性融合蛋白及其用途
|
|
MX368442B
(es)
|
2014-01-25 |
2019-10-02 |
Chengdu Kanghong Biotechnologies Co Ltd |
Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
|
|
WO2015140638A1
(en)
*
|
2014-03-18 |
2015-09-24 |
Korea Advanced Institute Of Science And Technology (Kaist) |
Glycosylated vegf decoy receptor fusion protein
|
|
CN106456757A
(zh)
|
2014-05-12 |
2017-02-22 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
MX382673B
(es)
|
2014-09-16 |
2025-03-13 |
Regeneron Pharma |
Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.
|
|
CA2966359A1
(en)
|
2014-11-07 |
2016-05-12 |
Lam Therapeutics, Inc. |
Apilimod for use in the treatment of renal cancer
|
|
TWI806150B
(zh)
|
2014-11-07 |
2023-06-21 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
MX2017009759A
(es)
|
2015-01-28 |
2017-10-27 |
Pfizer |
Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
|
|
US10342669B2
(en)
|
2015-04-07 |
2019-07-09 |
Zimmer, Inc. |
Convertible glenoid
|
|
WO2017001990A1
(en)
|
2015-06-28 |
2017-01-05 |
Allgenesis Biotherapeutics Inc. |
Fusion proteins for inhibiting angiogenesis
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
KR101685532B1
(ko)
*
|
2016-04-26 |
2016-12-13 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질
|
|
EP3412288A1
(en)
|
2017-06-08 |
2018-12-12 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating acne
|
|
EP3646887A4
(en)
|
2017-06-30 |
2021-03-24 |
Korea Advanced Institute of Science and Technology |
CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF
|
|
US20200255496A1
(en)
|
2017-09-18 |
2020-08-13 |
Amgen Inc. |
Vegfr-fc fusion protein formulations
|
|
CN109575140B
(zh)
|
2017-09-29 |
2021-02-23 |
北京比洋生物技术有限公司 |
靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
|
|
MX2020005170A
(es)
|
2017-11-17 |
2020-10-16 |
Amgen Inc |
Formulaciones de proteinas de fusion vegfr-fc.
|
|
AU2019212622B2
(en)
|
2018-01-26 |
2024-05-23 |
The Regents Of The University Of California |
Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
|
|
SG11202006712XA
(en)
|
2018-02-06 |
2020-08-28 |
Hoffmann La Roche |
Treatment of ophthalmologic diseases
|
|
DK4364724T3
(da)
|
2018-05-10 |
2025-12-22 |
Regeneron Pharma |
Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
|
|
BR112022010113A2
(pt)
|
2019-11-25 |
2022-09-06 |
Univ California |
Inibidores de vegf de longa ação para neovascularização intraocular
|